Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mohammed A. Qadeer is active.

Publication


Featured researches published by Mohammed A. Qadeer.


The American Journal of Gastroenterology | 2006

Proton Pump Inhibitor Therapy for Suspected GERD-Related Chronic Laryngitis: A Meta-Analysis of Randomized Controlled Trials

Mohammed A. Qadeer; Christopher O. Phillips; A. Rocio Lopez; David L. Steward; J. Pieter Noordzij; John M. Wo; Maria Suurna; Thomas E. Havas; Colin W. Howden; Michael F. Vaezi

OBJECTIVE:The role of proton pump inhibitors (PPIs) in suspected GERD-related chronic laryngitis (CL) is controversial. Hence, we performed a meta-analysis of the existing randomized controlled trials (RCTs) to evaluate the efficacy of PPIs in this disorder.METHODS:Data extracted from MEDLINE (1966 to August 2005), Cochrane Controlled Trials Register (1997 to August 2005), EMBASE (1980 to August 2005), ClinicalTrials.gov website, and meetings presentations (1999–2005). Published and unpublished randomized placebo-controlled trials of PPIs in suspected GERD-related CL were selected by consensus. Random effects model was utilized with standard approaches to quality assessment, sensitivity analysis, and an exploration of heterogeneity and publication bias. The primary outcome measure was defined as the proportion of patients with ≥50% reduction in self-reported laryngeal symptoms.RESULTS:Pooled data from 8 studies (N = 344, PPI 195, placebo 149; mean age 51 yr; males 55%; study duration 8–16 wk) were analyzed. No significant quantitative heterogeneity was found among the studies (χ2 = 11.22, P = 0.13). Overall, PPI therapy resulted in a nonsignificant symptom reduction compared to placebo (relative risk 1.28, 95% confidence interval 0.94–1.74). No clinical predictors of PPI response were identified on meta-regression analysis done at study level.CONCLUSIONS:PPI therapy may offer a modest, but nonsignificant, clinical benefit over placebo in suspected GERD-related CL. Validated diagnostic guidelines may facilitate the recognition of those patients most likely to respond favorably to PPI treatment.


Clinical Gastroenterology and Hepatology | 2005

Propofol Versus Traditional Sedative Agents for Gastrointestinal Endoscopy: A Meta-analysis

Mohammed A. Qadeer; John J. Vargo; Farah Khandwala; Rocio Lopez; Gregory Zuccaro

BACKGROUND & AIMS Even though propofol has better recovery profile than traditional agents, its use is limited because of the perception of increased complication rates. Because an adequately powered trial comparing risk of propofol with traditional agents is lacking, we performed a meta-analysis of the current literature. METHODS We searched Medline (1966-October 2004), EMBASE (1980-October 2004), and Cochrane controlled trials registry. The following 4 cardiopulmonary complications were assessed: hypoxia, hypotension, arrhythmias, and apnea. Procedures were divided into 3 groups: esophagogastroduodenoscopy group, colonoscopy group, and endoscopic retrograde cholangiopancreatography/endoscopic ultrasonography group. Pooled odds ratios for complications were calculated for all the procedures combined and then separately for the 3 groups. Random effects models were used for 2-proportion comparisons. RESULTS Of the 90 citations identified, 12 original studies qualified for this meta-analysis and included 1161 patients. Of these, 634 received propofol, and 527 received midazolam, meperidine, and/or fentanyl. Most of the included studies were randomized trials of moderate quality and nonsignificant heterogeneity (Cochran Q = 4.81, P = .90). Compared with traditional sedative agents, the pooled odds ratio with the use of propofol for developing hypoxia or hypotension for all the procedures combined was 0.74 (95% confidence interval [CI], 0.44-1.24); for EGD, 0.85 (95% CI, 0.33-2.17); for colonoscopy, 0.4 (95% CI, 0.2-0.79); and for ERCP/EUS, 1.07 (95% CI, 0.38-3.01). CONCLUSIONS Propofol sedation during colonoscopy appears to have lower odds of cardiopulmonary complications compared with traditional agents, but for other procedures, the risk of complications is similar.


Laryngoscope | 2005

Correlation between Symptoms and Laryngeal Signs in Laryngopharyngeal Reflux

Mohammed A. Qadeer; Jason Swoger; Claudio F. Milstein; Douglas M. Hicks; Jeff Ponsky; Joel E. Richter; Tom I. Abelson; Michael F. Vaezi

Objective/Hypothesis: Laryngopharyngeal reflux (LPR) is diagnosed by the presence of laryngeal signs and symptoms. Some studies have noted that signs and symptoms may be nonspecific and may have poor correlation. However, many such studies were either observational or had short‐term follow‐up. Therefore, we conducted subgroup analysis of a prospective concurrent controlled study with a 1 year follow‐up to study the correlation between signs and symptoms.


Journal of Thrombosis and Thrombolysis | 2005

Low–Molecular-Weight-Heparins as Periprocedural Anticoagulation for Patients on Long-Term Warfarin Therapy: A Standardized Bridging Therapy Protocol

Amir K. Jaffer; Mudassar Ahmed; Daniel J. Brotman; Lee Bragg; Niranjan Seshadri; Mohammed A. Qadeer; Allan L. Klein

Background: Over 2 million patients in North America are on warfarin anticoagulation therapy for prevention of thromboembolism. Suspension of warfarin therapy is often required to prepare patients for invasive procedures or surgeries. To protect these patients against thromboembolism while they are off warfarin, shorter-acting parenteral agents such as low-molecular-weight heparins (LMWHs) are often used. We conducted a retrospective observational study of our anticoagulation clinic patients to assess the safety and efficacy of LMWHs using a standardized protocol for periprocedural anticoagulation therapy.Methods: We included 69 consecutive patients who required interruption of their long-term warfarin therapy between August 2001 and August 2002, and were deemed by the treating physician to be at high enough risk for perioperative thromboembolism to justify bridging anticoagulation. We used a standard bridging therapy protocol in our anticoagulation clinic. Sixty-six patients received enoxaparin and three patients received tinzaparin for a mean duration of 7.7 days postoperatively. Outcomes were assessed for 30 days post-procedure. Safety outcomes included major bleeding and minor bleeding. Efficacy outcomes included thromboembolic event or death.Results: There were two major bleeding events, one minor bleeding event, and no cases of thromboembolism. Twelve patients experienced some bruising around the injection site.Conclusions: LMWH administration using our standard outpatient bridging protocol for perioperative anticoagulation appears to be relatively safe and efficacious, offering an alternative to inpatient administration of intravenous unfractionated heparin (UFH). Our study provides additional evidence to the limited published observational data regarding the safety and efficacy of LMWH as bridging therapy in the perioperative and periprocedural setting. Large, multicenter, randomized controlled trials are necessary to fully assess the safety and efficacy of LMWH for perioperative anticoagulation.Abbreviated AbstractWe conducted a retrospective observational study of 69 consecutive anticoagulation clinic patients on warfarin between August 2001 and August 2002, who were undergoing a procedure or surgery. The study was done to assess the safety and efficacy of an outpatient LMWH bridging protocol. Sixty-six patients received enoxaparin and three patients received tinzaparin for a mean duration of 3 days preoperatively and 7.7 days postoperatively. Outcomes were assessed for 30 days post-procedure. Safety outcomes included major bleeding and minor bleeding. Efficacy outcomes included thromboembolic event or death. There were two major bleeding events, one minor bleeding event, and no cases of thromboembolism. Twelve patients experienced some bruising around the injection site.


Laryngoscope | 2005

Is GERD a risk factor for laryngeal cancer

Mohammed A. Qadeer; Natalie Colabianchi; Michael F. Vaezi

Objective/Hypothesis: The significance of gastroesophageal reflux disease (GERD) in laryngeal cancer is controversial due to disparate studies. To evaluate the overall strength of the association of GERD with laryngeal cancer, we performed meta‐analysis of the original studies in literature.


Cleveland Clinic Journal of Medicine | 2010

Managing acute upper GI bleeding, preventing recurrences

Mazen Albeldawi; Mohammed A. Qadeer; John J. Vargo

Acute upper gastrointestinal (GI) bleeding is common and potentially life-threatening and needs a prompt assessment and aggressive medical management. All patients need to undergo endoscopy to diagnose, assess, and possibly treat any underlying lesion. In addition, patients found to have bleeding ulcers should receive a proton pump inhibitor, the dosage and duration of treatment depending on the endoscopic findings and clinical factors. Acute upper gastrointestinal bleeding is common and potentially life-threatening. It needs prompt assessment and aggressive medical management.


Laryngoscope | 2005

Does Acid Suppressive Therapy Reduce the Risk of Laryngeal Cancer Recurrence

Mohammed A. Qadeer; Rocio Lopez; Benjamin G. Wood; Ramon M. Esclamado; Marshall Strome; Michael F. Vaezi

Objective/Hypothesis: Gastroesophageal reflux disease (GERD) is implicated in laryngeal cancer pathogenesis and recurrence posttherapy. There are currently limited data on the effect of acid suppressive therapy in decreasing the recurrence of laryngeal cancer. Therefore, we conducted this study to identify potential effect of GERD and acid suppressive therapy on recurrences after larynx‐preserving therapies.


Cleveland Clinic Journal of Medicine | 2011

Recurrent abdominal pain after laparoscopic cholecystectomy.

Carole Macaron; Mohammed A. Qadeer; John J. Vargo

Four months after gallbladder surgery, her pain is back. Why?


Medical Clinics of North America | 2008

Severe Complications of Inflammatory Bowel Disease

Francisco Marrero; Mohammed A. Qadeer; Bret A. Lashner

Patients who have inflammatory bowel disease occasionally develop severe complications or emergency situations that require expert and expedited medical care, including toxic colitis, fistulas, abdominal abscesses, malignancy, primary sclerosing cholangitis, and pouchitis. Morbidity and mortality rates of Crohns disease and ulcerative colitis are increased over the expected rates in the unaffected population. Knowledge of the presenting features, natural history, and treatment of these complications should to lead to early and effective therapy and better outcomes.


The American Journal of Gastroenterology | 2009

BIS: hit or miss?

Mohammed A. Qadeer; John J. Vargo

To the Editor: We read with interest the article by Dr Stefan von Delius et al. regarding the utility of Bispectral Index (BIS) monitoring during colonoscopy (1). In contrast to other recent studies that did not find any significant benefit of BIS in the clinical monitoring of anesthesia or conscious sedation (2,3), the authors reported that a BIS value of above 73 would be a good target for moderate sedation.

Collaboration


Dive into the Mohammed A. Qadeer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael F. Vaezi

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge